Vera Therapeutics, Inc. (VERA) Key Metrics
VERA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.01B
- Enterprise value
- $1.96B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 5.8 10-yr median 5.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.05
VERA key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsVERA valuation Price multiples at each fiscal year-end price.
VERA returns How much profit the business earns on the capital it uses.
VERA per-share figures Results divided by the shares outstanding at year-end.
VERA financial health Debt, liquidity and how easily interest is covered.
VERA efficiency & capital use Working capital cycle and where the cash goes.
VERA valuation history
VERA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
VERA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
VERA cash returned to shareholders
VERA price vs earnings per share
VERA key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $3.25B | $2.34B | $656.8M | $514.1M | — | — | — |
| Enterprise value | $2.62B | $1.75B | $549.8M | $430.8M | — | — | — |
| Price / sales | — | — | 352.8 | — | — | — | — |
| Price / book | 5.4 | 4.1 | 6.5 | 6.7 | — | — | — |
| EV / sales | — | — | 295.3 | — | — | — | — |
| Earnings yield | −9.2% | −6.5% | −14.6% | −17.3% | — | — | — |
| Free cash flow yield | −7.4% | −5.8% | −14.0% | −13.2% | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Share price at fiscal year-end | $50.64 | $42.29 | $15.38 | $19.35 | $26.72 | — | — |
| Per share | |||||||
| Revenue per share | $0.00 | $0.00 | $0.04 | $0.00 | — | — | — |
| Earnings per share | −$4.66 | −$2.75 | −$2.25 | −$3.35 | — | — | — |
| Operating cash flow per share | −$3.75 | −$2.43 | −$2.16 | −$2.54 | — | — | — |
| Free cash flow per share | −$3.76 | −$2.45 | −$2.16 | −$2.55 | — | — | — |
| Cash per share | $11.12 | $11.58 | $3.76 | $4.32 | — | — | — |
| Book value per share | $9.41 | $10.43 | $2.38 | $2.89 | — | — | — |
| Tangible book value per share | $9.41 | $10.43 | $2.38 | $2.89 | — | — | — |
| Capex per share | $0.01 | $0.02 | $0.00 | $0.00 | — | — | — |
| Debt per share | $1.20 | $0.99 | $1.26 | $1.18 | — | — | — |
| Shares outstanding | 64.2M | 55.3M | 42.7M | 26.6M | — | — | — |
| Change in shares outstanding | +16.1% | +29.5% | +60.7% | — | — | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −50.7% | −44.8% | −107.5% | −121.6% | — | — | — |
| Return on assets (ROA) | −43.1% | −36.6% | −62.5% | −82.8% | −47.2% | −178.2% | −220.3% |
| Return on tangible assets | −40.8% | −23.2% | −54.7% | −67.8% | −38.9% | −97.9% | −220.3% |
| Financial health | |||||||
| Total debt | $77.3M | $54.6M | $53.7M | $31.3M | $4.9M | $2,000 | $132,000 |
| Cash & short-term investments | $714.6M | $640.9M | $160.7M | $114.7M | $79.7M | $53.7M | $3.2M |
| Net debt | −$637.3M | −$586.2M | −$107.0M | −$83.4M | −$74.8M | −$53.7M | −$3.1M |
| Debt / equity | 0.13 | 0.09 | 0.53 | 0.41 | 0.07 | — | — |
| Debt / assets | 0.11 | 0.08 | 0.31 | 0.24 | 0.06 | 0.00 | 0.02 |
| Current ratio | 13.64 | 25.67 | 7.71 | 4.91 | 10.73 | 22.55 | 3.36 |
| Quick ratio | 13.64 | 25.67 | 7.71 | 4.91 | 10.73 | 22.36 | 3.36 |
| Interest coverage | -41.9 | -21.9 | -26.9 | -91.6 | — | -289.5 | -234.5 |
| Working capital | $675.4M | $625.8M | $149.7M | $100.1M | $74.8M | $51.9M | $2.5M |
| Invested capital | −$32.8M | −$9.1M | −$5.3M | −$6.5M | −$5.2M | −$143.0M | −$39.6M |
| Tangible asset value | $604.5M | $577.2M | $101.7M | $76.9M | $69.6M | −$89.3M | −$36.5M |
| Net current asset value | $598.7M | $572.7M | $98.2M | $71.2M | $68.4M | −$89.6M | −$38.4M |
| Graham net-net per share | $9.14 | $10.21 | $2.03 | $2.26 | — | — | — |
| Capital allocation | |||||||
| Share buybacks (net) | $0 | $13,000 | $0 | $0 | $0 | — | — |
| Capex / revenue | — | — | 3.4% | — | — | — | — |
| Capex / depreciation | 1.35 | 9.26 | 3.00 | — | 0.00 | 0.39 | 0.25 |
| Stock-based compensation / revenue | — | — | 617.2% | — | — | — | — |
| R&D / revenue | — | — | 4,201.1% | — | — | — | — |
| SG&A / revenue | — | — | 1,277.5% | — | — | — | — |
| Efficiency | |||||||
| Days of inventory on hand | — | — | — | — | — | 686.4 | — |
| Days payables outstanding | 11,528.3 | 1,580.4 | -2,265.0 | -2,885.5 | 2,378.7 | 909.6 | 245.2 |
| Receivables turnover | 0.00 | 0.00 | — | — | — | 0.00 | — |
| Payables turnover | 0.03 | 0.23 | −0.16 | −0.13 | 0.15 | 0.40 | 1.49 |
| Inventory turnover | — | — | — | — | — | 0.53 | — |
| Asset turnover | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $3.5M | $3.8M | — | — | — | $52,000 | — |
| Average payables | $14.8M | $9.4M | $11.6M | $6.7M | $1.1M | $625,500 | $342,000 |
| Average inventory | — | — | — | — | — | $472,000 | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from VERA's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
VERA valuation and financial ratios
Vera Therapeutics earned a return on equity of −50.7% in fiscal 2025. It ended the year with $77.3 million of debt and $714.6 million in cash and short-term investments, a net cash position of $637.3 million.
See the VERA income statement, the VERA chart for price history, or the VERA stock overview for the latest quote and news.
VERA key metrics FAQ
What is Vera Therapeutics's return on equity?
Vera Therapeutics's return on equity (ROE) was −50.7% in fiscal 2025: net income of -$299.6 million on average shareholders' equity of $590.8 million.
How much debt does Vera Therapeutics have?
Vera Therapeutics had total debt of $77.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.13 and more cash than debt.
What is Vera Therapeutics's free cash flow yield?
Vera Therapeutics generated -$241.7 million of free cash flow in fiscal 2025, a free cash flow yield of −7.4% on its market value at year-end ($3.3 billion).
What is Vera Therapeutics's current ratio?
Vera Therapeutics's current ratio was 13.64 at the end of fiscal 2025: current assets were 13.64 times current liabilities.